VIKING THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.31 USD | +7.91% |
|
+17.17% | +299.30% |
| 04-25 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday | MT |
| 04-24 | Viking Therapeutics Q1 Loss Widens; Shares Fall After Hours | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 8.19B 654B |
|---|---|---|---|---|---|
| Net income 2024 * | -119M -9.49B | Net income 2025 * | -172M -13.72B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 895M 71.36B | Net cash position 2025 * | 749M 59.77B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-66.5
x | P/E ratio 2025 * |
-48
x | Employees | 28 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.93% |
More Fundamentals
* Assessed data
More news
Latest transcript on Viking Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | +7.91% | ||
| 1 week | +17.17% | ||
| Current month | -9.38% | ||
| 1 month | -9.38% | ||
| 3 months | +247.73% | ||
| 6 months | +704.22% | ||
| Current year | +299.30% |
1 week
62.56
74.64
1 month
61.6482.00
Current year
17.2399.41
1 year
8.2899.41
3 years
2.0299.41
5 years
2.0299.41
10 years
0.8899.41
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Lian
FOU | Founder | 58 | 23/09/12 |
Gregory Zante
DFI | Director of Finance/CFO | 53 | 04/01/16 |
Marianne Mancini
COO | Chief Operating Officer | 59 | 30/04/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Matthew Foehr
BRD | Director/Board Member | 51 | 30/04/14 |
J. Singleton
BRD | Director/Board Member | 71 | 30/04/14 |
Charles Rowland
BRD | Director/Board Member | 65 | 30/06/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.13% | 2 M€ | -.--% | ||
| 0.06% | 7 M€ | -.--% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 74.31 | +7.91% | 3,535,445 |
| 25/04/24 | 68.86 | +5.82% | 3,526,931 |
| 24/04/24 | 65.07 | +0.22% | 2,584,595 |
| 23/04/24 | 64.93 | +1.69% | 2,032,588 |
| 22/04/24 | 63.85 | +0.68% | 1,562,386 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.
Calendar
21/05/2024
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
74.31
USD
Average target price
108.4
USD
Spread / Average Target
+45.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +299.30% | 8.19B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.49% | 22.15B | |
| -17.37% | 21.02B | |
| -8.68% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- VKTX Stock
